Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1226 (8%) in mild atopic asthma
NCT02334553Phase 2Completed
- Sponsor
- SolAeroMed
- Start
- Feb 2015
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing S1226 (8%) with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 120 minutes. Started Feb 2015; status: completed.
02
Drugs
S-1226
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02334553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334553.